TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Eating Disorder Examination-Questionnaire (EDE-Q)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Male body dissatisfaction scale (MBDS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endothelial Cell Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strength of pelvic floor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HPV 6 GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV 11 GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV 16 GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV 18 GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of doses administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced One or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to clinical treatment of glaucoma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Growth of Geographic Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in Drusen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrements of 24-hour urine albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients With no Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tracheal tube cuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of hospitalized pneumonia cases
Endpoint domain: Mortality/survival
Primary endpoint: Blood loss in ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neuromuscular fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: total number of adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: abnormal laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients who completed the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Achieved Hematologic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of Alvocidib as Evaluated by Incidence of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: rectal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of antibodies induced
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients who become pregnant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: microcirculation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma adipokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Length (in days) of the latent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Admission to NICU (in days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean objective wake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Re-accumulation of the patient's peri-tonsillar abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum tolerated dose of oxaliplatin and fluorouracil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (histological remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: short-term functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite of the First Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction or Nonfatal Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Composite of the First Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Change From Baseline in Abdominal Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: The Fagerstrom Test for Nicotine Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Subject to Reach Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune cell compositions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oral Health Impact Profile (OHIP-14)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 Grade 3 or higher immune-related adverse events [irAEs]
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-free survival (TFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HVLT-R test total words recalled scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gastrointestinal Symptom Rating Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: standardized mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: standardized hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: standardized 30-day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Granulocyte/PMN Cell Collection Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Clinical Chemistry and Hematology Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Vital Signs and 12-Lead Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Spirometry Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: S. aureus colonization level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: bacterial virulence profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Default mode network functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity and specificity of cervical PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal plasma concentration (Cmax) of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in sense of smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mPTP calcium sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of target vocalizations and/or approximations during sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of target vocalizations and/or approximations at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parent-reported vocalizations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parents' level of concern regarding opioid use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of Alopecia Tool (SALT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Normalization of Vitamin D Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of fetal growth restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Clinic Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vertigo Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device/procedure related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of respiratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: AHI Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ureteral Stent Symptom Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ASAS20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma-glucagon Area Under Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical Asthma Exacerbation (CAE) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mesial migration of anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remifentanil Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rrSO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cvSO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Scale (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 5-Repetition Sit-to-Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain interference with daily activities TP1
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain interference with daily activities TP2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in patients mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stability of hydraulic resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Re-operations due to re-herniation
Endpoint domain: Adverse events/effects
Primary endpoint: safety and tolerability of STA-9090 (ganetespib)
Endpoint domain: Adverse events/effects
Primary endpoint: anti-neoplastic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pharmacokinetics of STA-9090 (ganetespib)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccination prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients achieving R0 resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Injection site pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean antibodies titer (GMT) at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection rate at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Skin Irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Skin Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Patients Achieving a Response Based on M-protein or Free Light Chains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of weekly Taxotere
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural Symptom Course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amino acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mTOR activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol-related consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biomarkers of bone turnover (P1NP and CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calcium regulating hormones (PTH and 1,25 dihydroxyvitamin D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in minimal JSW of the index hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Brain Oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ocular chlamydia infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in levels of Anti-gE antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in number of subjects with a vaccine response for anti-gE antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of oral HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subjective appetite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet induced thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intestinal apoA-I production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary loss measured by pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: self reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weight gain during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of mutation / specific polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of miosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cotinine-verified 7-day Point Prevalence Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 42-day PCR corrected adequate clinical and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of levosimendan and OR 1896 1855 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Clinical Benefit Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as Assessed by Toxicity Grades and Treatment Modifications
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence rate of gastroesophogeal reflux disease (GERD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Regression of Angina without Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regression of ST-T and T-waves alterations of Myocardial Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RBC K Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to First Use of Supplemental Pain Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change over time in social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change over time in perceived social isolation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rates of detection of medical-legal issues
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of radioactive dose recovered in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total percentage of radioactive dose recovered from both urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of total radioactivity in blood and plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of AZD1722 in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients Achieving Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ginigval thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Antibiotic-associated Diarrhea Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 1-year stroke rate
Endpoint domain: Mortality/survival
Primary endpoint: Aspiration
Endpoint domain: Adverse events/effects
Primary endpoint: Newborn APGAR Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events (side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Morning Peak Expiratory Flow (mPEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Memorial Delirium Assessment Scale (MDAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium Motor Subtyping Scale (DMSS-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedman Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Surgery Site CFU Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of known adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of new adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Association, risk factors, severity and incidence of immune-related adverse drug reactions/events
Endpoint domain: Adverse events/effects
Primary endpoint: Association, risk factors, severity and incidence of serious adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse drug reactions in special population
Endpoint domain: Adverse events/effects
Primary endpoint: Chlamydia infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Contraceptive use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Leukocytes morphological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incremental area under the plasma glucose versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant neurological examination abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes